Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

The Systemic Treatment of Melanoma.

Terheyden P, Krackhardt A, Eigentler T.

Dtsch Arztebl Int. 2019 Jul 22;116(29-30):497-504. doi: 10.3238/arztebl.2019.0497.

2.

Key Features Relevant to Select Antigens and TCR From the MHC-Mismatched Repertoire to Treat Cancer.

Audehm S, Glaser M, Pecoraro M, Bräunlein E, Mall S, Klar R, Effenberger M, Albers J, Bianchi HO, Peper J, Yusufi N, Busch DH, Stevanović S, Mann M, Antes I, Krackhardt AM.

Front Immunol. 2019 Jun 28;10:1485. doi: 10.3389/fimmu.2019.01485. eCollection 2019.

3.

Gene editing enables T-cell engineering to redirect antigen specificity for potent tumor rejection.

Albers JJ, Ammon T, Gosmann D, Audehm S, Thoene S, Winter C, Secci R, Wolf A, Stelzl A, Steiger K, Ruland J, Bassermann F, Kupatt C, Anton M, Krackhardt AM.

Life Sci Alliance. 2019 Mar 15;2(2). pii: e201900367. doi: 10.26508/lsa.201900367. Print 2019 Apr.

4.

Enhanced Safety and Efficacy of Oncolytic VSV Therapy by Combination with T Cell Receptor Transgenic T Cells as Carriers.

Melzer MK, Zeitlinger L, Mall S, Steiger K, Schmid RM, Ebert O, Krackhardt A, Altomonte J.

Mol Ther Oncolytics. 2018 Dec 8;12:26-40. doi: 10.1016/j.omto.2018.12.001. eCollection 2019 Mar 29.

5.

T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target.

Mayer KE, Mall S, Yusufi N, Gosmann D, Steiger K, Russelli L, Bianchi HO, Audehm S, Wagner R, Bräunlein E, Stelzl A, Bassermann F, Weichert W, Weber W, Schwaiger M, D'Alessandria C, Krackhardt AM.

Theranostics. 2018 Nov 28;8(21):6070-6087. doi: 10.7150/thno.27275. eCollection 2018.

6.

[Immuno-Oncology: A Brief Overview].

Kobold S, Krackhardt A, Schlösser H, Wolf D.

Dtsch Med Wochenschr. 2018 Jul;143(14):1006-1013. doi: 10.1055/a-0623-9147. Epub 2018 Jul 13. Review. German.

PMID:
30005434
7.

Evaluation of the new continuous mononuclear cell collection protocol versus an older version on two different apheresis machines.

Spoerl S, Wäscher D, Nagel S, Peschel C, Verbeek M, Götze K, Krackhardt AM.

Transfusion. 2018 Jul;58(7):1772-1780. doi: 10.1111/trf.14644. Epub 2018 May 6.

PMID:
29732573
8.

Clinical translation and regulatory aspects of CAR/TCR-based adoptive cell therapies-the German Cancer Consortium approach.

Krackhardt AM, Anliker B, Hildebrandt M, Bachmann M, Eichmüller SB, Nettelbeck DM, Renner M, Uharek L, Willimsky G, Schmitt M, Wels WS, Schüssler-Lenz M.

Cancer Immunol Immunother. 2018 Apr;67(4):513-523. doi: 10.1007/s00262-018-2119-y. Epub 2018 Jan 29. Review.

PMID:
29380009
9.

Identification and Characterization of Neoantigens As Well As Respective Immune Responses in Cancer Patients.

Bräunlein E, Krackhardt AM.

Front Immunol. 2017 Nov 30;8:1702. doi: 10.3389/fimmu.2017.01702. eCollection 2017. Review.

10.

Specific Adoptive Cellular Immunotherapy in Allogeneic Stem Cell Transplantation.

Audehm S, Krackhardt AM.

Oncol Res Treat. 2017;40(11):691-696. doi: 10.1159/000484051. Epub 2017 Oct 26.

11.

Combined PET/MRI: Global Warming-Summary Report of the 6th International Workshop on PET/MRI, March 27-29, 2017, Tübingen, Germany.

Bailey DL, Pichler BJ, Gückel B, Antoch G, Barthel H, Bhujwalla ZM, Biskup S, Biswal S, Bitzer M, Boellaard R, Braren RF, Brendle C, Brindle K, Chiti A, la Fougère C, Gillies R, Goh V, Goyen M, Hacker M, Heukamp L, Knudsen GM, Krackhardt AM, Law I, Morris JC, Nikolaou K, Nuyts J, Ordonez AA, Pantel K, Quick HH, Riklund K, Sabri O, Sattler B, Troost EGC, Zaiss M, Zender L, Beyer T.

Mol Imaging Biol. 2018 Feb;20(1):4-20. doi: 10.1007/s11307-017-1123-5.

12.

[Progress in cancer immunotherapy].

Krackhardt AM, Heinrich B.

MMW Fortschr Med. 2017 Aug;159(14):48-53. doi: 10.1007/s15006-017-9949-y. Review. German. No abstract available.

PMID:
28924719
13.

Isolation and functional characterization of hepatitis B virus-specific T-cell receptors as new tools for experimental and clinical use.

Wisskirchen K, Metzger K, Schreiber S, Asen T, Weigand L, Dargel C, Witter K, Kieback E, Sprinzl MF, Uckert W, Schiemann M, Busch DH, Krackhardt AM, Protzer U.

PLoS One. 2017 Aug 8;12(8):e0182936. doi: 10.1371/journal.pone.0182936. eCollection 2017.

14.

Tools to define the melanoma-associated immunopeptidome.

Bräunlein E, Krackhardt AM.

Immunology. 2017 Dec;152(4):536-544. doi: 10.1111/imm.12803. Epub 2017 Aug 28. Review.

15.

In-depth Characterization of a TCR-specific Tracer for Sensitive Detection of Tumor-directed Transgenic T Cells by Immuno-PET.

Yusufi N, Mall S, Bianchi HO, Steiger K, Reder S, Klar R, Audehm S, Mustafa M, Nekolla S, Peschel C, Schwaiger M, Krackhardt AM, D'Alessandria C.

Theranostics. 2017 Jun 15;7(9):2402-2416. doi: 10.7150/thno.17994. eCollection 2017.

16.

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.

Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, Heinzerling L, Krackhardt AM, Loquai C, Markovic SN, Joseph RW, Markey K, Utikal JS, Weishaupt C, Goldinger SM, Sondak VK, Zager JS, Schadendorf D, Khushalani NI.

Eur J Cancer. 2017 Apr;75:47-55. doi: 10.1016/j.ejca.2017.01.009. Epub 2017 Feb 17.

PMID:
28214657
17.

Formin like 1 expression is increased on CD4+ T lymphocytes in spontaneous autoimmune uveitis.

Degroote RL, Uhl PB, Amann B, Krackhardt AM, Ueffing M, Hauck SM, Deeg CA.

J Proteomics. 2017 Feb 10;154:102-108. doi: 10.1016/j.jprot.2016.12.015. Epub 2017 Jan 3.

PMID:
28057602
18.

Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry.

Bassani-Sternberg M, Bräunlein E, Klar R, Engleitner T, Sinitcyn P, Audehm S, Straub M, Weber J, Slotta-Huspenina J, Specht K, Martignoni ME, Werner A, Hein R, H Busch D, Peschel C, Rad R, Cox J, Mann M, Krackhardt AM.

Nat Commun. 2016 Nov 21;7:13404. doi: 10.1038/ncomms13404.

19.

Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis.

Spoerl S, Peter R, Wäscher D, Götze K, Verbeek M, Peschel C, Krackhardt AM.

Transfusion. 2017 Jan;57(1):115-121. doi: 10.1111/trf.13883. Epub 2016 Nov 18.

PMID:
27859332
20.
21.

Transgenic antigen-specific, HLA-A*02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity.

Schirmer D, Grünewald TG, Klar R, Schmidt O, Wohlleber D, Rubío RA, Uckert W, Thiel U, Bohne F, Busch DH, Krackhardt AM, Burdach S, Richter GH.

Oncoimmunology. 2016 Apr 25;5(6):e1175795. doi: 10.1080/2162402X.2016.1175795. eCollection 2016 Jun.

22.

Immuno-PET Imaging of Engineered Human T Cells in Tumors.

Mall S, Yusufi N, Wagner R, Klar R, Bianchi H, Steiger K, Straub M, Audehm S, Laitinen I, Aichler M, Peschel C, Ziegler S, Mustafa M, Schwaiger M, D'Alessandria C, Krackhardt AM.

Cancer Res. 2016 Jul 15;76(14):4113-23. doi: 10.1158/0008-5472.CAN-15-2784. Epub 2016 Jun 28.

23.

Optimized Lentiviral Transduction Protocols by Use of a Poloxamer Enhancer, Spinoculation, and scFv-Antibody Fusions to VSV-G.

Anastasov N, Höfig I, Mall S, Krackhardt AM, Thirion C.

Methods Mol Biol. 2016;1448:49-61. doi: 10.1007/978-1-4939-3753-0_4.

PMID:
27317172
24.

Human HLA-A*02:01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T cells specifically inhibit Ewing sarcoma growth in vitro and in vivo.

Blaeschke F, Thiel U, Kirschner A, Thiede M, Rubio RA, Schirmer D, Kirchner T, Richter GHS, Mall S, Klar R, Riddell S, Busch DH, Krackhardt A, Grunewald TG, Burdach S.

Oncotarget. 2016 Jul 12;7(28):43267-43280. doi: 10.18632/oncotarget.9218.

25.

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.

Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM.

Eur J Cancer. 2016 Jun;60:190-209. doi: 10.1016/j.ejca.2016.02.025. Epub 2016 Apr 13.

PMID:
27085692
26.

Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.

Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Forschner A, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM.

Eur J Cancer. 2016 Jun;60:210-25. doi: 10.1016/j.ejca.2016.02.024. Epub 2016 Apr 13.

PMID:
27084345
27.

Quantitative Analysis of the Association Angle between T-cell Receptor Vα/Vβ Domains Reveals Important Features for Epitope Recognition.

Hoffmann T, Krackhardt AM, Antes I.

PLoS Comput Biol. 2015 Jul 17;11(7):e1004244. doi: 10.1371/journal.pcbi.1004244. eCollection 2015 Jul.

28.

Long-term experiences in cryopreservation of mobilized peripheral blood stem cells using a closed-bag system: a technology with potential for broader application.

Spoerl S, Peter R, Wäscher D, Verbeek M, Menzel H, Peschel C, Krackhardt AM.

Transfusion. 2015 Nov;55(11):2702-8. doi: 10.1111/trf.13206. Epub 2015 Jul 14.

PMID:
26172379
29.

T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.

Dargel C, Bassani-Sternberg M, Hasreiter J, Zani F, Bockmann JH, Thiele F, Bohne F, Wisskirchen K, Wilde S, Sprinzl MF, Schendel DJ, Krackhardt AM, Uckert W, Wohlleber D, Schiemann M, Stemmer K, Heikenwälder M, Busch DH, Richter G, Mann M, Protzer U.

Gastroenterology. 2015 Oct;149(4):1042-52. doi: 10.1053/j.gastro.2015.05.055. Epub 2015 Jun 5.

PMID:
26052074
30.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J.

Lancet Oncol. 2015 Apr;16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8. Epub 2015 Mar 18.

PMID:
25795410
31.

Therapeutic targeting of naturally presented myeloperoxidase-derived HLA peptide ligands on myeloid leukemia cells by TCR-transgenic T cells.

Klar R, Schober S, Rami M, Mall S, Merl J, Hauck SM, Ueffing M, Admon A, Slotta-Huspenina J, Schwaiger M, Stevanović S, Oostendorp RA, Busch DH, Peschel C, Krackhardt AM.

Leukemia. 2014 Dec;28(12):2355-66. doi: 10.1038/leu.2014.131. Epub 2014 Apr 16.

PMID:
24736212
32.

TCR-ligand koff rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer.

Nauerth M, Weißbrich B, Knall R, Franz T, Dössinger G, Bet J, Paszkiewicz PJ, Pfeifer L, Bunse M, Uckert W, Holtappels R, Gillert-Marien D, Neuenhahn M, Krackhardt A, Reddehase MJ, Riddell SR, Busch DH.

Sci Transl Med. 2013 Jul 3;5(192):192ra87. doi: 10.1126/scitranslmed.3005958.

33.

Proteomic investigation of the interactome of FMNL1 in hematopoietic cells unveils a role in calcium-dependent membrane plasticity.

Han Y, Yu G, Sarioglu H, Caballero-Martinez A, Schlott F, Ueffing M, Haase H, Peschel C, Krackhardt AM.

J Proteomics. 2013 Jan 14;78:72-82. doi: 10.1016/j.jprot.2012.11.015. Epub 2012 Nov 24.

PMID:
23182705
34.

Isolation of human MHC class II-restricted T cell receptors from the autologous T-cell repertoire with potent anti-leukaemic reactivity.

Weigand LU, Liang X, Schmied S, Mall S, Klar R, Stötzer OJ, Salat C, Götze K, Mautner J, Peschel C, Krackhardt AM.

Immunology. 2012 Nov;137(3):226-38. doi: 10.1111/imm.12000.

35.

Poloxamer synperonic F108 improves cellular transduction with lentiviral vectors.

Höfig I, Atkinson MJ, Mall S, Krackhardt AM, Thirion C, Anastasov N.

J Gene Med. 2012 Aug;14(8):549-60. doi: 10.1002/jgm.2653.

PMID:
22887595
36.

A single TCR alpha-chain with dominant peptide recognition in the allorestricted HER2/neu-specific T cell repertoire.

Liang X, Weigand LU, Schuster IG, Eppinger E, van der Griendt JC, Schub A, Leisegang M, Sommermeyer D, Anderl F, Han Y, Ellwart J, Moosmann A, Busch DH, Uckert W, Peschel C, Krackhardt AM.

J Immunol. 2010 Feb 1;184(3):1617-29. doi: 10.4049/jimmunol.0902155. Epub 2009 Dec 30.

37.

Formin-like 1 (FMNL1) is regulated by N-terminal myristoylation and induces polarized membrane blebbing.

Han Y, Eppinger E, Schuster IG, Weigand LU, Liang X, Kremmer E, Peschel C, Krackhardt AM.

J Biol Chem. 2009 Nov 27;284(48):33409-17. doi: 10.1074/jbc.M109.060699. Epub 2009 Oct 8.

38.

Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies.

Schuster IG, Busch DH, Eppinger E, Kremmer E, Milosevic S, Hennard C, Kuttler C, Ellwart JW, Frankenberger B, Nössner E, Salat C, Bogner C, Borkhardt A, Kolb HJ, Krackhardt AM.

Blood. 2007 Oct 15;110(8):2931-9. Epub 2007 Jul 12.

39.

Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX.

Krackhardt AM, Witzens M, Harig S, Hodi FS, Zauls AJ, Chessia M, Barrett P, Gribben JG.

Blood. 2002 Sep 15;100(6):2123-31.

40.

T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy.

Krackhardt AM, Harig S, Witzens M, Broderick R, Barrett P, Gribben JG.

Blood. 2002 Jul 1;100(1):167-73.

41.

Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues.

Harig S, Witzens M, Krackhardt AM, Trojan A, Barrett P, Broderick R, Zauls AJ, Gribben JG.

Blood. 2001 Nov 15;98(10):2999-3005.

42.

Targeting Folates by Carboxypeptidase G2: Potential Applications in Anticancer Therapy.

Krackhardt A, Schwartz S, Thiel E.

Onkologie. 2000 Dec;23(6):538-543.

PMID:
11441258
43.

Generation of cytotoxic T lymphocytes against native and altered peptides of human leukocyte antigen-A*0201 restricted epitopes from the human epithelial cell adhesion molecule.

Trojan A, Witzens M, Schultze JL, Vonderheide RH, Harig S, Krackhardt AM, Stahel RA, Gribben JG.

Cancer Res. 2001 Jun 15;61(12):4761-5.

44.

Carboxypeptidase G2 rescue in a 79 year-old patient with cranial lymphoma after high-dose methotrexate induced acute renal failure.

Krackhardt A, Schwartz S, Korfel A, Thiel E.

Leuk Lymphoma. 1999 Nov;35(5-6):631-5.

PMID:
10609804
45.

Stem cell transplantation for indolent lymphoma.

Krackhardt A, Gribben JG.

Curr Opin Hematol. 1999 Nov;6(6):388-93. Review.

PMID:
10546792

Supplemental Content

Loading ...
Support Center